News
SpringWorks Therapeutics (SWTX) gains EMA panel endorsement for Mirdametinib, a treatment for neurofibromatosis type 1. Read ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible resultsSome results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback